Telix Pharmaceuticals Limited announced it has entered into a commercialisation and partnership agreement with DuChemBio Co Ltd. (DuChemBio), the leading South Korean radiopharmaceutical company, for Telix's prostate cancer imaging product TLX591-CDx (68Ga-PSMA-11). DuChemBio has the largest radiopharmaceutical manufacturing network serving the field of Nuclear Medicine in Korea. Telix has granted exclusive rights to DuChemBio to commercialise TLX591-CDx for prostate cancer imaging in South Korea.

The parties will cooperate to attain a marketing authorisation for the product from the Korean Ministry of Food and Drug Safety (MFDS).